{"classes":[{"categories":[{"measurements":[{"groupId":"OG000","value":"9"}]}],"title":"Antibody Sero(+) Pre- and Post-treatment"},{"categories":[{"measurements":[{"groupId":"OG000","value":"2"}]}],"title":"Antibody Sero(-) Pre- and Post-treatment"},{"categories":[{"measurements":[{"groupId":"OG000","value":"1"}]}],"title":"Antibody Sero(-) Pre-treatment, (+) Post-treatment"},{"categories":[{"measurements":[{"groupId":"OG000","value":"5"}]}],"title":"CD4+ Pre- and Post-treatment"},{"categories":[{"measurements":[{"groupId":"OG000","value":"6"}]}],"title":"CD4- Pre- and Post-treatment"},{"categories":[{"measurements":[{"groupId":"OG000","value":"1"}]}],"title":"CD4 Not Evaluable"},{"categories":[{"measurements":[{"groupId":"OG000","value":"7"}]}],"title":"CD8+ Pre- and Post-treatment"},{"categories":[{"measurements":[{"groupId":"OG000","value":"5"}]}],"title":"CD8- Pre- and Post-treatment"},{"categories":[{"measurements":[{"groupId":"OG000","value":"11"}]}],"title":"Increase of ≥ 2 Cytokines Post-treatment"},{"categories":[{"measurements":[{"groupId":"OG000","value":"11"}]}],"title":"IL-6 Increase Post-treatment"},{"categories":[{"measurements":[{"groupId":"OG000","value":"5"}]}],"title":"TNF-α Increase Post-treatment"},{"categories":[{"measurements":[{"groupId":"OG000","value":"5"}]}],"title":"IFN-γ Increase Post-treatment"},{"categories":[{"measurements":[{"groupId":"OG000","value":"3"}]}],"title":"IL-2 Increase Post-treatment"},{"categories":[{"measurements":[{"groupId":"OG000","value":"2"}]}],"title":"IL-Iβ Increase Post-treatment"},{"categories":[{"measurements":[{"groupId":"OG000","value":"2"}]}],"title":"IL-8 Increase Post-treatment"},{"categories":[{"measurements":[{"groupId":"OG000","value":"2"}]}],"title":"IL-10 Increase Post-treatment"},{"categories":[{"measurements":[{"groupId":"OG000","value":"1"}]}],"title":"IL-12 Increase Post-treatment"},{"categories":[{"measurements":[{"groupId":"OG000","value":"0"}]}],"title":"IL-5 Increase Post-treatment"}],"denoms":[{"counts":[{"groupId":"OG000","value":"12"}],"units":"Participants"}],"description":"Serum NY-ESO-1-specific immune responses evaluated by humoral immunity (antibodies measured by ELISA), cellular immunity (CD8+ T-cell and CD4+ T-cell measured by ELISPOT), and cytokine activation (measured by ELISA) from pre-treatment through 4 weeks after the last dose of study treatment. \\[Note: CD = cluster of differentiation; IFN =interferon; IL = interleukin; TNF = tumor necrosis factor\\]","groups":[{"description":"Subjects received MBV twice weekly by subcutaneous injection at a starting dose of 250 EU (dose level 1), with intrasubject dose escalations for each subsequent administration in the absence of a DLT until the desired pyrogenic effect was observed.","id":"OG000","title":"Cohort 1 (Immune Response Analysis Set)"}],"paramType":"NUMBER","populationDescription":"The Immune Response Analysis Set comprises all subjects who achieved the desired pyrogenic effects.","reportingStatus":"POSTED","timeFrame":"Up to 3 months","title":"Number of Participants With Serum NY-ESO-1-specific Immune Responses","type":"SECONDARY","unitOfMeasure":"participants"}